Marker Therapeutics Revenue Estimates for Next Quarter Analysis

Marker Therapeutics, Inc. (MRKR)

1.97 -0.22 (-10.05%) USD | NASDAQ | Jan 22, 12:25

View Revenue Estimates for Next Quarter for MRKR.
Upgrade now.

Sep '18

Jan '19

May '19

285.00

270.00

255.00

240.00

View Revenue Estimates for Next Quarter Chart

Start Trial

View Historical Data

Start Trial

View Revenue Estimates for Next Quarter Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

View Revenue Estimates for Next Quarter Benchmarks

Start Trial

Viridian Therapeutics, Inc.	Upgrade
ADMA Biologics, Inc.	Upgrade
Kiniksa Pharmaceuticals International Plc	Upgrade
Neurocrine Biosciences, Inc.	Upgrade
AIM ImmunoTech, Inc.	Upgrade

Revenue Estimates for Current Quarter	Upgrade
Revenue Estimates for Current Fiscal Year	Upgrade
Revenue Estimates for Next Fiscal Year	Upgrade
EPS Estimates for Current Quarter	Upgrade
EPS Estimates for Next Quarter	Upgrade
EPS Estimates for Current Fiscal Year	Upgrade
EPS Estimates for Next Fiscal Year	Upgrade